Trial Profile

A Study Comparing Prospective Use of Imipenem/Cilastatin/Relebactam (IMI/REL) to Retrospective Data Using Meropenem/ Vabobactam (MVB) and Ceftazidime/Avibactam (CZA) in Treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae Infections

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cilastatin/imipenem/relebactam (Primary) ; Avibactam/ceftazidime; Meropenem/vaborbactam
Indications Enterobacteriaceae infections; Gram-negative infections; Klebsiella infections
Focus Therapeutic Use

13 Jan 2023 Status changed from recruiting to withdrawn prior to enrolment.
16 Jun 2022 Planned End Date changed from 31 May 2022 to 1 Oct 2023.
16 Jun 2022 Planned primary completion date changed from 31 May 2022 to 1 Jun 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com